Liao, Daoyong, Su, Xiaoling, Wang, Jingyun et al. · Frontiers in immunology · 2023 · DOI
This review examines how a molecule called MALP-2, derived from a bacterium linked to ME/CFS, affects the immune system. Researchers found that MALP-2 can activate immune cells in ways that might help fight infections and heal tissues. The molecule is simple to make and could potentially be developed into treatments for various conditions.
Understanding the immune mechanisms triggered by Mycoplasma fermentans—a pathogen that has been hypothesized to contribute to ME/CFS—could illuminate how certain infections trigger prolonged immune dysfunction in ME/CFS patients. This review identifies MALP-2 as a potential therapeutic target or vaccine component, offering a mechanistic foundation for developing treatments that might address both infection-related and immune-mediated aspects of ME/CFS.
This review does not provide clinical evidence that MALP-2-based therapies improve ME/CFS outcomes in patients, nor does it establish that Mycoplasma fermentans is a definitive cause of ME/CFS. The study presents mechanistic potential in isolated immune cell models and animal studies without demonstrating efficacy, safety, or applicability in human ME/CFS populations.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →